NEW YORK, March 5 – Mitsubishi Chemical has joined forces with Fujitsu, a large Japanese electronics and information technology company, to use genomics data to research and develop pharmaceuticals, the Wall Street Journal reported Monday.
The two firms said in a statement that they hoped to promote genomics-based drugs and personalized medicine to create a "new life science society.” While the alliance has no specific projects yet, a joint task force will hash out the details of the alliance and develop a research focus.
"We have agreed to cooperate in creating new businesses as well as boosting existing businesses by combining biotechnology and information technology, which represent the key to technological development in the 21st century," the firms said in a statement.
Mitsubishi Chemical, the largest producer of chemicals in Japan, has recently shifted its attention to bolstering its life science and biotechnology businesses. Most recently, Mitsubishi acquired the rights to sell HTS Biosystem’s bioanalysis system for protein detection in Japan.
Fujitsu is also working with Daiichi Pharmaceutical and Celestar Lexico-Sciences, a biotech start-up, to develop genomics-based drugs.